Skip to main content

Post-menopausal Vasomotor Symptoms

2
Pipeline Programs
2
Companies
18
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
BAY3427080Phase 1/25 trials
Active Trials
NCT06219902Completed64Est. Apr 2024
NCT05587296Active Not Recruiting474Est. Jun 2028
NCT05481528Completed51Est. Apr 2023
+2 more trials
NeRRe Therapeutics
NeRRe TherapeuticsUK - Stevenage
1 program
1
BAY3427080Phase 1/2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080
BayerBAY3427080

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 2,530 patients across 18 trials

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Start: Oct 2022Est. completion: Jun 2028474 patients
Phase 3Active Not Recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

Start: Oct 2021Est. completion: Oct 2023400 patients
Phase 3Completed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

Start: Aug 2021Est. completion: Nov 2023396 patients
Phase 3Completed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause

Start: Aug 2021Est. completion: Feb 2024628 patients
Phase 3Completed

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

Start: Nov 2018Est. completion: Nov 2019199 patients
Phase 2Completed

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

Start: Aug 2016Est. completion: Mar 201776 patients
Phase 1/2Completed

A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

Start: Jan 2024Est. completion: Apr 202464 patients
Phase 1Completed

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

Start: Aug 2022Est. completion: Apr 202351 patients
Phase 1Completed

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Start: Aug 2022Est. completion: Nov 202220 patients
Phase 1Completed

A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years

Start: May 2022Est. completion: Jul 202216 patients
Phase 1Completed

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

Start: May 2022Est. completion: Jun 202218 patients
Phase 1Completed

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

Start: Oct 2021Est. completion: Oct 202231 patients
Phase 1Completed

A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults

Start: Sep 2021Est. completion: Feb 202214 patients
Phase 1Completed

A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.

Start: Sep 2021Est. completion: Jan 202216 patients
Phase 1Completed

A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults

Start: Aug 2021Est. completion: Mar 202262 patients
Phase 1Completed

A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants

Start: Jun 2021Est. completion: Mar 202233 patients
Phase 1Completed

A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants

Start: May 2021Est. completion: Sep 202116 patients
Phase 1Completed

Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

Start: Apr 2021Est. completion: Jun 202116 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.